Filing Flows › TG Therapeutics (TGTX) › Free cash flow
TG Therapeutics (TGTX) free cash flow by quarter
TG Therapeutics' free cash flow was $39.0M in Q2 2026 (second quarter 2026), +99% from Q4 2025. Over the last 3 quarters it ranged from $7.4M (Q2 2025) to $39.0M (Q2 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $39.0M | +99% | +427% |
| Q4 2025 | $19.6M | +165% | — |
| Q2 2025 | $7.4M | — | — |
Q2 2026 at a glance
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is TG Therapeutics' free cash flow?
TG Therapeutics' free cash flow was $39.0M in Q2 2026 (second quarter 2026), +99% from Q4 2025.
How has TG Therapeutics' free cash flow changed?
Over the last 3 quarters it ranged from $7.4M (Q2 2025) to $39.0M (Q2 2026).